Registered title, quoted from ClinicalTrials.gov
Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients
An open trial on multiple myeloma, registered on ClinicalTrials.gov. Led by Affiliated People's Hospital of Ningbo University; 6 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 7
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
- Lead sponsorAffiliated People's Hospital of Ningbo University宁波大学医学院附属医院NingboHospital page
- Study siteFirst Affiliated Hospital of Wenzhou Medical University温州医科大学附属第一医院WenzhouHospital page
- Study siteFirst Affiliated Hospital, Zhejiang University浙江大学医学院附属第一医院HangzhouHospital page
- Study siteSecond Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University温州医科大学附属第二医院WenzhouHospital page
- Study siteShaoxing People's Hospital绍兴市人民医院HangzhouHospital page
- Study siteTaizhou Hospital, Wenzhou Medical University温州医科大学附属台州医院TaizhouHospital page
- Study siteTongde Hospital浙江省立同德医院HangzhouHospital page
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT06520176, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 3
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (3 points)Hide the checklist
18 years to 75 years; sex: all
Registered eligibility fields
3. Eastern Cooperative Oncology Group (ECOG) performance status of 0\~1.
Inclusion criterion 3
2. Serum direct bilirubin (DBIL)>2× upper limit of normal (ULN).
Exclusion criterion 2
3. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >3× ULN.
Exclusion criterion 3
4. Serum creatinine clearance rate≤30%.
Exclusion criterion 4
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; earlier treatment; scans and measurable lesions; other conditions the trial excludes; pregnancy, breastfeeding and contraception.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06520176, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- 1. Patients newly diagnosed as multiple myeloma.
- 2. Indication for ASCT.
- 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0\~1.
- 4. Life expectancy ≥ 3 months.
- 5. Subjects must be able to understand the protocol and sign the informed consent.
Exclusion Criteria:
- 1. Cardiac function class II or higher or cardiac ejection fraction <40%.
- 2. Serum direct bilirubin (DBIL)>2× upper limit of normal (ULN).
- 3. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >3× ULN.
- 4. Serum creatinine clearance rate≤30%.
- 5. Patients with active infection.
- 6. Previously received hematopoietic stem cell mobilization.
Quoted from ClinicalTrials.gov, NCT06520176, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT06520176, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.